CONMED Corp
CNMD- Exchange
- NYSE
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0000816956
No open-market purchases or sales by CONMED Corp insiders were filed in the last 90 days; 248 institutions reported holding it in 13F filings for Q2 2026, worth $1.12B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 16, 2026
- $1.47B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +13 vs. previous quarter
- 248
- 13F valueReported value at the end of Q2 2026
- $1.12B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.37B
- +5.2% year over year
- Net income, FY2025
- $47.1M
- −64.5% year over year
- Free cash flow, FY2025
- $150.9M
- −2.0% year over year
- Revenue, Q3 FY2026
- $335.6M
- −0.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.86M
- Shares sold short
- Change
- −51.0K
- −2.7% vs. previous
- Days to cover
- 4.29
- At average daily volume
Superinvestors holding CNMD, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CNMD at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by CONMED Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 (view filing) | Nov 21 | 3 days | Glaze RichardChief Information Officer | SSale | −257 | $41.21 | −$10.6K | −100.0%0 after | 10b5-1 |
| Nov 7, 2025 (view filing) | Nov 6 | 1 day | Garner Todd WExecutive Vice President & CFO | SSale | −3.50K | $43.00 | −$150.5K | −65.6%1.84K after | 10b5-1 |
| Sep 15, 2025 (view filing) | Sep 12 | 3 days | Farkas CharlesDirector | SSale | −2.00K | $53.53 | −$107.1K | −11.9%14.9K after | 2 lots |
| Aug 8, 2025 (view filing) | Aug 7 | 1 day | Garner Todd WExecutive Vice President & CFO | SSale | −598 | $52.45 | −$31.4K | −100.0%0 after | |
| May 6, 2025 (view filing) | May 5 | 1 day | Farkas CharlesDirector | SSale | −4.00K | $56.94 | −$227.8K | −19.7%16.3K after | |
| Feb 13, 2025 (view filing) | Feb 11 | 2 days | Glaze RichardChief Information Officer | SSale | −257 | $65.35 | −$16.8K | −100.0%0 after | |
| Jun 17, 2024 (view filing) | Jun 14 | 3 days | Peters Stanley W IIIPresident AS and AET | SSale | −4.00K | $71.82 | −$287.3K | −98.4%63 after | |
| May 14, 2024 (view filing) | May 13 | 1 day | Bronson David MDirector | PPurchase | +1.35K | $72.09 | +$97.3K | +8.9%16.5K after | |
| May 10, 2024 (view filing) | May 8 | 2 days | Schwarzentraub Barbara JDirector | PPurchase | +1.44K | $69.26 | +$99.9K | New position1.44K after | |
| May 8, 2024 (view filing) | May 6 | 2 days | Aronson Martha GoldbergDirector | PPurchase | +2.00K | $70.98 | +$142.0K | New position2.00K after |
Top 10 13F holders, Q2 2026
See all 248 holdersThe largest institutional positions in CONMED Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,820,739 | $157.8M | 0.00% | −4,434−0.1% | Reduced |
| Earnest Partners LLC | 2,505,295 | $82.0M | 0.30% | −64,358−2.5% | Reduced |
| Vanguard Portfolio Management LLC | 2,188,761 | $71.6M | 0.00% | +112,344+5.4% | Added |
| Fuller & Thaler Asset Management, Inc. | 1,579,917 | $51.7M | 0.14% | −61,849−3.8% | Reduced |
| State Street Corp | 1,417,468 | $46.4M | 0.00% | +33,450+2.4% | Added |
| Vanguard Capital Management LLC | 1,355,728 | $44.4M | 0.00% | −28,314−2.0% | Reduced |
| Bank of America Corp | 1,341,409 | $43.9M | 0.00% | −61,211−4.4% | Reduced |
| Dimensional Fund Advisors LP | 1,317,370 | $43.1M | 0.01% | −75,550−5.4% | Reduced |
| SEI Investments Co | 988,151 | $32.3M | 0.03% | −16,564−1.6% | Reduced |
| Invenomic Capital Management LP | 842,162 | $27.6M | 1.65% | −92,439−9.9% | Reduced |
Holders of 5% or more of CNMD
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of CONMED Corp.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 15.10%4.68M shares | – | Jul 18, 20251 filing | Jul 18, 2025 | SEC |
| Vanguard Portfolio Management LLC | 13G | 6.87%2.12M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.25%1.62M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |